

2020

INFORMATION ON JAPANESE REGULATORY AFFAIRS

*Regulatory Information Task Force
Japan Pharmaceutical Manufacturers Association*

Pharmaceutical Administration and Regulations in Japan

Japan Pharmaceutical Manufacturers Association

2020

<http://www.jpma.or.jp/about/issue/gratis/index2.html> (Japanese)

<http://www.jpma.or.jp/english/parj/whole.html> (English)

Pharmaceutical Administration and Regulations in Japan

This file contains information concerning pharmaceutical administration, regulations, and new drug development in Japan updated annually by the English RA Information Task Force, International Affairs Committee, Japan Pharmaceutical Manufacturers Association (JPMA). The contents are not abstracts of governmental rules or regulations but concise descriptions of most current practices by regulatory agencies and the industry that the working group complies. The file does not contain anything related to forecasts. The file is available also at the homepage of National Institute of Health Sciences (<http://www.nihs.go.jp/kanren/iyaku.html>).

Japan Pharmaceutical Manufacturers Association

<http://www.jpma.or.jp/english/>

Table of Contents

CHAPTER 1	1
ORGANIZATION AND FUNCTION OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE	
1. PHARMACEUTICAL SAFETY AND ENVIRONMENTAL HEALTH BUREAU (PSEHB)	2
1.1 General Affairs Division	2
1.2 Pharmaceutical Evaluation Division	2
1.3 Medical Device Evaluation Division	2
1.4 Pharmaceutical Safety Division	3
1.5 Compliance and Narcotics Division	3
1.6 Blood and Blood Products Division	4
2. HEALTH POLICY BUREAU	4
2.1 Economic Affairs Division	4
2.2 Research and Development Division	4
3. NATIONAL INSTITUTE OF HEALTH SCIENCES	5
4. PHARMACEUTICALS AND MEDICAL DEVICES AGENCY, AN INDEPENDENT ADMINISTRATIVE ORGANIZATION	5
4.1 Office of Review Administration	6
4.2 Office of Review Management	6
4.3 Office of New Drug I	6
4.4 Office of New Drug II	6
4.5 Office of New Drug III	6
4.6 Office of New Drug IV	7
4.7 Office of New Drug V	7
4.8 Office of Cellular and Tissue-based Products	7
4.9 Office of Vaccines and Blood Products	7
4.10 Office of OTC/Quasi-drugs	7
4.11 Office of Generic Drugs	7
4.12 Office of Non-clinical and Clinical Compliance	7
4.13 Office of Medical Devices I	7
4.14 Office of Medical Devices II	7
4.15 Office of Standards and Compliance for Medical Devices	8
4.16 Office of In Vitro Diagnostics	8
4.17 Office of Manufacturing Quality and Vigilance for Medical Devices	8
4.18 Office of Manufacturing Quality for Drugs	8
4.19 Office of Informatics and Management for Safety	8
4.20 Office of Pharmacovigilance I	8
4.21 Office of Pharmacovigilance II	8
4.22 Office of International Programs	8
4.23 Office of International Cooperation	8
4.24 Office of Advanced Evaluation with Electronic Data	9
4.25 Office of Medical Informatics and Epidemiology	9
4.26 Kansai Branch	9
4.27 Hokuriku Branch	9
5. NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (NIBIOHN)	9
6. JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT (AMED)	9
7. PHARMACEUTICAL AFFAIRS AND FOOD SANITATION COUNCIL (PAFSC)	9
8. NATIONAL INSTITUTE OF INFECTIOUS DISEASES	10
CHAPTER 2	15
PHARMACEUTICAL LAWS AND REGULATIONS	
1. PHARMACEUTICAL LAWS	15
2. PHARMACEUTICAL AND MEDICAL DEVICE ACT	15
3. OUTLINE OF PHARMACEUTICAL REGULATIONS	17
3.1 Definition of Drugs	17
3.2 Classification of Drugs	17
3.3 License for Manufacturing/Marketing Businesses	19
3.4 License for Manufacturing Business and Accreditation of Overseas Manufacturers	20
3.5 Manufacturing/Marketing Approvals	22
3.6 Good Manufacturing Practice (GMP)	22
3.7 Drug Master File (MF)	23
3.8 Drug Retail Seller Licensing	24
3.9 Labeling and Package Inserts	24
3.10 Proper Advertisement	25
3.11 Good Laboratory Practice (GLP)	26
3.12 Good Clinical Practice (GCP)	26
3.13 Trial Conducted from a Compassionate Viewpoint (expanded trial)	27
3.14 Patient-requested Therapy System	28
3.15 Good Post-marketing Study Practice (GPSP)	28
3.16 Reexamination	28
3.17 Reevaluation	29
3.18 Adverse Drug Reaction (ADR) and Infection Reporting	29
3.19 Risk Management Plan (RMP)	29
3.20 Dissemination of Information	30

3.21	Measures related to the Law Concerning Access to Information Held by Administrative Organizations	30	6.4	Safety Measures against Bovine Spongiform Encephalitis (BSE)	49
3.22	Patent System	31			
3.23	Drug Abuse Control	32			
3.24	Countermeasures for Counterfeit Prescription Drug	33			
4.	MARKETING APPROVALS	33		CHAPTER 3	57
4.1	Drug Marketing Approvals	33			
4.2	Marketing Approval Reviews	33			
4.3	Manufacturing/Marketing Approval Application with Electronic Data	35			
4.4	Priority Review System and Designation of Drug Products for Priority Reviews	36			
4.5	Restrictive Approval System	37			
4.6	Orphan Drugs	37			
4.7	Drugs for Pediatric Use	37			
4.8	Unapproved Drugs and Drugs of Off-label Use	38			
4.9	Packaging Strategy for World-first Products	39			
4.10	Regulatory Science Strategy Consultations for Regenerative Medicine Products (former Regulatory Strategy Consultations)	40			
4.11	Approval System Implemented to Promote the Application of Regenerative Medicine Including Cellular and Tissue-Based Products for Commercialization (Approval with Conditions and Time Limit)	41			
4.12	Conditional Accelerated Approval System for Pharmaceuticals	41			
4.13	Guidelines for Promoting Optimal Use	41			
4.14	Biosimilar Products	42			
4.15	Combination Products	42			
4.16	Codevelopment	43			
4.17	Transfer of Marketing Approvals	43			
4.18	Approval Applications for Drugs Manufactured Overseas	44			
4.19	Issuing of Certificates for Exported Drugs by MHLW	44			
5.	JAPANESE PHARMACOPOEIA AND OTHER STANDARDS	45		CHAPTER 4	116
5.1	Japanese Pharmacopoeia (JP)	45			
5.2	Standards Based on Article 42 of the Pharmaceutical and Medical Device Ac	46			
5.3	Standards for Biological Materials	47			
5.4	Quality Standards Based on Notifications	48			
5.5	Government Batch Test	48			
6.	PHARMACEUTICAL SUPERVISION	48			
6.1	Pharmaceutical Supervision	48			
6.2	Product Recalls	48			
6.3	Prevention of Medical Accidents Caused by Drugs, etc	49			
	DRUG DEVELOPMENT	57			
	1. PROCESS FROM DEVELOPMENT TO APPROVAL	57			
	1.1 Development of New Drugs	57			
	1.2 Procedures for Clinical Trials	58			
	1.3 Safety information on Adverse Reactions and Infections during the Study	60			
	1.4 Interview advice meetings	61			
	1.5 Approval review	65			
	1.6 Compliance review	66			
	1.7 GMP compliance inspection	67			
	2. DATA REQUIRED FOR APPROVAL APPLICATIONS	70			
	2.1 Data to be Attached to Approval Application of Drugs	73			
	3. GUIDELINES CONCERNING DRUG APPROVAL APPLICATIONS	74			
	3.1 Quality and Nonclinical Studies	75			
	3.2 Clinical Studies	79			
	4. OTHER	88			
	4.1 Biotechnological Products	88			
	4.2 Drugs Using Materials of Human or Animal Origin as Ingredients (Biological Products)	88			
	4.3 Biosimilar Products	89			
	4.4 Public Disclosure of Information on New Drug Development	90			
	4.5 ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use)	91			
	POST-MARKETING SURVEILLANCE OF DRUGS	116			
	1. GVP	119			
	2. GPSP	126			
	3. PAPER COMPLIANCE REVIEW AND ON-SITE GPSP SURVEYS OF DATA FOR REEXAMINATION AND REEVALUATION	130			
	4. ADVERSE DRUG REACTIONS AND INFECTIONS REPORTING SYSTEM	130			
	4.1 Adverse Drug Reaction and Infectious Disease Reporting System by Pharmaceutical				

4.2	Companies	130	3.2	Safety Flash Report (Blue Letters)	156
4.2	Drug and Medical Device Safety Information Reporting System by Medical Personnel.....	133	3.3	Commentaries on "Precautions" in Package Inserts of New Drugs	157
4.3	Reporting of Adverse Drug Reactions from Patients	134	3.4	Distribution of Information by 'Notices of Revision of Precautions'	157
4.4	WHO International Drug Monitoring Program.....	134	3.5	Dissemination of Information for Drugs That Have Completed Reexamination or Reevaluation	158
5.	PERIODIC INFECTION REPORTS FOR BIOLOGICAL PRODUCTS (ARTICLE 68-14 AND 68-24 IN THE LAW)	135	3.6	Dissemination of ADR Information by the Pharmaceuticals and Medical Devices Safety Information (Information on Adverse Reactions to Drugs)	158
6.	REEXAMINATION SYSTEM (ARTICLE 14-4 AND 23-29 OF THE PHARMACEUTICAL AFFAIRS LAW).....	135	3.7	Dissemination of Information by Drug Safety Update	158
6.1	Designation for Reexamination of Drugs.....	136	3.8	Medical Guides for Patients.....	159
6.2	Periodic Safety Reports (Article 63 of the Enforcement Regulations of the Law).....	136	3.9	Manual for Handling Disorders due to Adverse Drug Reactions	159
6.3	Data Required for Reexamination Applications and Reexamination Procedures	137	4.	ELECTRONIC INFORMATION DISSEMINATION	159
7.	REEVALUATION SYSTEM (ARTICLES 14-6 AND 23-31 OF THE LAW).....	138	5.	PACKAGE INSERTS OF NON-PRESCRIPTION DRUGS	160
	CHAPTER 5	145	6.	PACKAGE INSERTS OF GUIDANCE-MANDATORY DRUGS	160
	SUPPLY AND DISSEMINATION OF DRUG SAFETY MANAGEMENT INFORMATION	145			
1.	PACKAGE INSERTS	145		CHAPTER 6	166
1.1	New Guidance on the Style and Format of Package Inserts	147		HEALTH INSURANCE PROGRAMS AND DRUG PRICING IN JAPAN	166
1.2	Headings and Their Sequence in Package Inserts	148	1.	HISTORY OF HEALTH INSURANCE PROGRAMS	166
1.3	Precautions	149	2.	MEDICAL BENEFITS OFFERED UNDER HEALTH INSURANCE PROGRAMS	167
1.4	Labeling of Excipients	150	3.	REIMBURSEMENT OF MEDICAL FEES	167
1.5	Entries for Biological Products	150	4.	NATIONAL HEALTH INSURANCE PRICE LIST	168
1.6	Brand Names of Prescriptions Drugs	151	5.	PRICING FORMULA FOR REIMBURSEMENT PRICE REVISIONS OF DRUGS LISTED IN THE NHI PRICE LIST	168
1.7	Consultation Works Related to Revision of Package Insert	152	6.	RECENT REVISIONS OF THE NHI PRICE LIST	170
1.8	Information about English Package Insert	152	7.	DETERMINATION OF REIMBURSEMENT PRICES FOR NEW DRUGS	171
2.	INFORMATION TO SUPPLEMENT PACKAGE INSERTS	152	8.	ENTRY OF GENERIC DRUGS IN THE NHI PRICE LIST	172
2.1	Outline of Prescription Pharmaceutical Product Information	153	9.	ISSUES RELATED TO THE USE OF DETERMINATION OF UNAPPROVED DRUGS AND OFF-LABEL USE	172
2.2	Pharmaceutical Interview Forms (IF)	153			
2.3	Commentaries on "Precautions" in Package Inserts of New Drugs	154			
3.	SUPPLY AND DISSEMINATION OF SAFETY MANAGEMENT INFORMATION	154			
3.1	Distribution of Emergency Safety Information (Yellow Letters)	155			

Fig. 1 Organization of Ministry of Health, Labour, and Welfare (Health-related organizations only).....	11
Fig. 2 Organization of Pharmaceutical Safety and Environmental Health Bureau (PSEHB) and Pharmaceuticals and Medical Devices Agency (PMDA).....	12
Fig. 3 Organization of the Pharmaceutical Affairs and Food Sanitation Council (PAFSC).....	14
Fig. 4 Flowchart of Patent-Life Extension	51
Fig. 5 Flowchart of Approval Review.....	52
Fig. 6 Procedure for manufacturing and marketing approval of drugs for overseas manufacturers in Japan.....	53
Fig. 7 Flowchart of Drug Listing in Japanese Pharmacopoeia	54
Table 1 List of Main Controlled Substances.....	55
Table 2 Divisions of the Pharmaceutical and Food Safety Bureau in Charge of Certification Work	56
Fig. 8 Flowchart of New Drug Development and Approval	93
Fig. 9 Timeline of the standard process of new drug approval (ordinary review products)...	94
Fig. 10 Timeline of the standard process of new drug approval (priority review products).....	95
Table 3 Data to be Submitted with an Application for Approval to Manufacture/Market: A New Prescription Drug.....	96
Table 4 Data to be Submitted with an Application for a Non-prescription Drug	98
Table 5 Classification of Clinical Studies According to Objectives.....	100
Table 6 List of Major Guidelines, etc. on Physicochemical Properties, Specifications, and Tests Methods	101
Table 7 List of Major Guidelines, etc. on Toxicity Tests	103
Table 8 List of Major Guidelines, etc. on Pharmacological Studies	104
Table 9 List of Major Guidelines, etc. on Pharmacokinetic Studies.....	104
Table 10 List of Major Guidelines, etc. on Bioequivalence Studies	105
Table 11 List of Major Guidelines, etc. on Clinical Evaluation.....	106
Table 12 List of Major Guidelines, etc. Related to Biotechnology	109
Fig. 11 Organization of ICH Common Technical Documents	110
Fig. 12 Correlation between Development Phases and Types of Study	111
Table 13 ICH topics and guidelines - Progress of harmonization	112
Fig. 13 Pharmaceutical Post-marketing Surveillance System.....	140
Fig. 14 Post-marketing Collection and Reporting of Pharmaceutical Safety Information	141
Fig. 15 Collection and Reporting of Pharmaceutical Safety Information	142
Fig. 16 Reexamination System	143
Fig. 17 Reevaluation System	144
Fig. 18 Layout of Package Insert Based on Revised Guidelines for Preparation (Image)	162
Fig. 19 Standard Procedures for Revision of Package Insert at PMDA (1)	164
Fig. 20 Standard Procedures for Revision of Package Insert at PMDA (2)	165
Fig. 21 Reimbursement Pricing Flow-sheet for New Drugs	174
Fig. 22 Correlation between the Time of Marketing Approval Based on Pharmaceutical Affairs Law and the Time of Entry in the NHI Price List	175
Table 14 History of Reimbursement Price Revisions	176
Table 15 Annual Changes in Drug Expenses and Estimated Divergence Rate	178
Table 16 Requirements for Applying Premiums	186